Response to Comments: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies (DL38176)

This document is a response-to-comments notice for MolDX LCD L38176 concerning NGS lab-developed tests for myeloid malignancies and does not itself state clinical coverage, exclusions, frequency limits, or claim documentation requirements. The public comment period was 04/25/2019–06/09/2019, the notice period began 12/26/2019, and the LCD became effective 02/09/2020.

"This document is a response to public comments for MolDX LCD L38176 (Next-Generation Sequencing LDTs for myeloid malignancies); the public comment period ran 2019-04-25 to 2019-06-09, the notice pe..."

Sign up to see full coverage criteria, indications, and limitations.